Apatinib Combined With EGFR-TKI for Advanced Slow-progressed EGFR-TKI Resistant NSCLC
NCT03428022
·
clinicaltrials.gov ↗
PHASE3
Phase
UNKNOWN
Status
54
Enrollment
OTHER
Sponsor class
Conditions
NSCLC
Apatinib
EGFR-TKI
Interventions
DRUG:
Apatinib（Tab. 500mg/d） combined with EGFR-TKI（as previously）
Sponsor
Shenzhen People's Hospital